To test the hypothesis that ApN signalling activation could alleviate cancer cachexia, we performed an interventional study by administering AdipoRon, a synthetic agonist of ApN receptors, in two distinct murine models of cancer cachexia, one acute, the C26 mice, and one subacute, the ApcMin/+ mice. Here, ANPEP is linked to cancer.